Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

ClinicalTrials.gov ID: NCT01536015

Public ClinicalTrials.gov record NCT01536015. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.

Study identification

NCT ID
NCT01536015
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
25 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2011
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013
Last update posted
Jul 31, 2014

2012 – 2013

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
011 Birmingham Alabama
001 Gilbert Arizona
022 Fountain Valley California
017 Irvine California
028 Pasadena California
015 Sunnyvale California
008 Gainesville Florida
009 Miami Florida
010 Ormond Beach Florida
006 Sunrise Florida
032 Annapolis Maryland
027 Lincoln Nebraska
016 Commack New York
026 Mineola New York
034 Charlotte North Carolina
002 Raleigh North Carolina
007 Salisbury North Carolina
021 Toledo Ohio
023 Tulsa Oklahoma
031 Cordova Tennessee
018 Memphis Tennessee
014 Houston Texas
030 Richmond Virginia
003 Virginia Beach Virginia
012 Kirkland Washington
013 Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01536015, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2014 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01536015 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →